These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 25746294

  • 1. Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial.
    Seidman L, Kroll R, Howard B, Ricciotti N, Hsieh J, Weiss H.
    Contraception; 2015 Jun; 91(6):495-502. PubMed ID: 25746294
    [Abstract] [Full Text] [Related]

  • 2. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
    van Heusden AM, Fauser BC.
    Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
    [Abstract] [Full Text] [Related]

  • 3. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
    Rossmanith WG, Steffens D, Schramm G.
    Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens.
    Vandever MA, Kuehl TJ, Sulak PJ, Witt I, Coffee A, Wincek TJ, Reape KZ.
    Contraception; 2008 Mar; 77(3):162-70. PubMed ID: 18279685
    [Abstract] [Full Text] [Related]

  • 5. A phase 1, multicentre, open-label study to evaluate ovarian follicular activity and hormone levels with an extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation.
    Kroll R, Seidman L, Ricciotti N, Howard B, Weiss H.
    Eur J Contracept Reprod Health Care; 2015 Mar; 20(4):249-58. PubMed ID: 25522805
    [Abstract] [Full Text] [Related]

  • 6. Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen.
    Archer DF, Kovalevsky G, Ballagh SA, Grubb GS.
    Contraception; 2009 Sep; 80(3):245-53. PubMed ID: 19698816
    [Abstract] [Full Text] [Related]

  • 7. Ovarian activity during regular oral contraceptive use.
    Crosignani PG, Testa G, Vegetti W, Parazzini F.
    Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
    [Abstract] [Full Text] [Related]

  • 8. Shorter pill-free interval in combined oral contraceptives decreases follicular development.
    Spona J, Elstein M, Feichtinger W, Sullivan H, Lüdicke F, Müller U, Düsterberg B.
    Contraception; 1996 Aug; 54(2):71-7. PubMed ID: 8842582
    [Abstract] [Full Text] [Related]

  • 9. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
    Anttila L, Kunz M, Marr J.
    Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
    [Abstract] [Full Text] [Related]

  • 10. A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen.
    Duijkers IJ, Heger-Mahn D, Drouin D, Skouby S.
    Eur J Contracept Reprod Health Care; 2015 Nov; 20(6):419-27. PubMed ID: 26073333
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study.
    Duijkers IJ, Klipping C, Zimmerman Y, Appels N, Jost M, Maillard C, Mawet M, Foidart JM, Coelingh Bennink HJ.
    Eur J Contracept Reprod Health Care; 2015 Nov; 20(6):476-89. PubMed ID: 26394847
    [Abstract] [Full Text] [Related]

  • 12. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition.
    Mulders TM, Dieben TO.
    Fertil Steril; 2001 May; 75(5):865-70. PubMed ID: 11334895
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function.
    Duijkers I, Klipping C, Kinet V, Jost M, Bastidas A, Foidart JM.
    Contraception; 2021 Jun; 103(6):386-393. PubMed ID: 33689786
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate.
    Rible RD, Taylor D, Wilson ML, Stanczyk FZ, Mishell DR.
    Contraception; 2009 Mar; 79(3):182-8. PubMed ID: 19185670
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol.
    Kroll R, Ackerman R, Feldman R, Howard B, Weiss H, Hsieh J, Ricciotti N.
    Contraception; 2016 Mar; 93(3):249-56. PubMed ID: 26499407
    [Abstract] [Full Text] [Related]

  • 18. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
    Hemrika DJ, Slaats EH, Kennedy JC, de Vries Robles-Korsen TJ, Schoemaker J.
    J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
    [Abstract] [Full Text] [Related]

  • 19. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
    Klipping C, Duijkers I, Trummer D, Marr J.
    Contraception; 2008 Jul; 78(1):16-25. PubMed ID: 18555813
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.